Potentially inappropriate medication use among hypertensive older African-American adults.

Mohsen Bazargan, James L Smith, Ebony O King
Author Information
  1. Mohsen Bazargan: Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA, 90005, USA. mobazarg@cdrewu.edu.
  2. James L Smith: Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA, 90005, USA.
  3. Ebony O King: Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA, 90005, USA.

Abstract

BACKGROUND: Inappropriate use of medications, particularly among minority older adults with co-morbidity, remains a major public health concern. The American Geriatrics Society (AGS) reports that Potentially Inappropriate Medication (PIM) continues to be prescribed for older adults, despite evidence of poor outcomes. The main objective of this study was to examine the prevalence of PIM use among underserved non-institutionalized hypertensive older African-American adults. Furthermore, this study examines potential correlations between PIM use and the number and type of chronic conditions.
METHODS: This cross-sectional study is comprised of a convenience sample of 193 hypertensive non-institutionalized African-American adults, aged 65 years and older recruited from several senior housing units located in underserved areas of South Los Angeles. The updated 2015 AGS Beers Criteria was used to identify participants using PIMs.
RESULTS: Almost one out of two participants had inappropriate medication use. While the average number of PIMs taken was 0.87 drugs, the range was from one to seven medications. Almost 23% of PIMs were due to drugs with potential drug-drug interactions. The most common PIM was the use of proton pump inhibitors (PPI) and Central Nervous System (CNS) active agents. Nearly 56% of PIMs potentially increased the risk of falls and fall-associated bone fractures. The use of PIMs was significantly higher among participants who reported a higher number of chronic conditions. Nearly 70% of participants with PIM use reported suffering from chronic pain.
CONCLUSIONS: The major reason for high levels of polypharmacy, PIMs, and drug interactions is that patients suffer from multiple chronic conditions. But it may not be possible or necessary to treat all chronic conditions. Therefore, the goals of care should be explicitly reviewed with the patient in order to determine which of the many chronic conditions has the greatest impact on the life goals and/or functional priorities of the patient. Those drugs that have a limited impact on the patient's functional priorities and that may cause harmful drug-drug interactions can be reduced or eliminated, while the remaining medications can focus on the most important functional priorities of the patient.

Keywords

References

  1. J Am Geriatr Soc. 2015 Nov;63(11):2227-46 [PMID: 26446832]
  2. J Am Geriatr Soc. 2005 Oct;53(10):1774-9 [PMID: 16181179]
  3. J Am Geriatr Soc. 2016 Oct;64(10):2116-2121 [PMID: 27590566]
  4. Am J Phys Med Rehabil. 2000 Jan-Feb;79(1):30-9 [PMID: 10678600]
  5. Geriatr Nurs. 2011 Sep-Oct;32(5):350-6 [PMID: 21962885]
  6. Ann Pharmacother. 2016 Jul;50(7):599-603 [PMID: 27083921]
  7. PLoS One. 2012;7(8):e43617 [PMID: 22928004]
  8. BMC Geriatr. 2006 Jan 11;6:1 [PMID: 16403236]
  9. Geriatr Gerontol Int. 2012 Jul;12(3):506-14 [PMID: 22239067]
  10. Med Clin North Am. 2009 May;93(3):753-69 [PMID: 19427503]
  11. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jun;113(6):714-21 [PMID: 22668700]
  12. Am J Geriatr Pharmacother. 2010 Apr;8(2):136-45 [PMID: 20439063]
  13. BMC Geriatr. 2017 Mar 11;17(1):65 [PMID: 28284206]
  14. Eur J Clin Pharmacol. 2015 Oct;71(10):1255-62 [PMID: 26249851]
  15. Ethn Dis. 2014 Autumn;24(4):431-7 [PMID: 25417425]
  16. Am J Geriatr Pharmacother. 2011 Feb;9(1):11-23 [PMID: 21459305]
  17. J Hypertens. 2017 Jan;35(1):55-62 [PMID: 27906837]
  18. J Aging Health. 2016 Apr;28(3):403-25 [PMID: 26115668]
  19. J Pharmacol Pharmacother. 2012 Jan;3(1):81-2 [PMID: 22368433]
  20. Hawaii J Med Public Health. 2014 Jan;73(1):11-8 [PMID: 24470982]
  21. Consult Pharm. 2010 Jan;25(1):36-40 [PMID: 20211815]
  22. J Hypertens. 2017 Jun;35(6):1145-1154 [PMID: 28106662]
  23. CMAJ Open. 2017 Sep 25;5(3):E729-E733 [PMID: 28947426]
  24. J Gen Intern Med. 2014 Apr;29(4):602-7 [PMID: 24366395]
  25. Br J Clin Pharmacol. 2005 Aug;60(2):137-44 [PMID: 16042666]
  26. Age Ageing. 2005 Nov;34(6):626-32 [PMID: 16267190]
  27. J Am Geriatr Soc. 2017 Jan;65(1):83-90 [PMID: 27666895]
  28. J Clin Pharm Ther. 2006 Oct;31(5):485-91 [PMID: 16958827]
  29. J Am Med Dir Assoc. 2017 Mar 1;18(3):211-220 [PMID: 28131719]
  30. J Aging Health. 2016 Feb;28(1):118-38 [PMID: 26129701]
  31. Eur J Clin Pharmacol. 2005 Jan;60(11):813-9 [PMID: 15599504]
  32. Res Aging. 2017 Apr;39(4):501-525 [PMID: 28285579]
  33. BMC Cardiovasc Disord. 2017 Jul 17;17(1):189 [PMID: 28716041]
  34. Am J Geriatr Psychiatry. 2005 Jul;13(7):572-80 [PMID: 16009733]
  35. J Aging Res. 2017;2017:6026358 [PMID: 28630771]
  36. Health Serv Res. 2017 Aug;52(4):1534-1549 [PMID: 27686781]
  37. J Pharm Pract. 2017 Feb;30(1):82-88 [PMID: 26702027]
  38. Med Care. 2009 Aug;47(8):826-34 [PMID: 19584762]
  39. J Alzheimers Dis. 2016 Nov 19;55(2):691-701 [PMID: 27716668]
  40. Lancet. 2007 Jul 14;370(9582):173-184 [PMID: 17630041]
  41. J Am Dent Assoc. 2017 May;148(5):298-307 [PMID: 28284416]
  42. J Aging Health. 2015 Aug;27(5):894-918 [PMID: 25659747]
  43. J Gerontol A Biol Sci Med Sci. 2002 Jul;57(7):M473-8 [PMID: 12084812]
  44. J Gerontol A Biol Sci Med Sci. 2006 Apr;61(4):394-8 [PMID: 16611707]
  45. J Racial Ethn Health Disparities. 2017 Jun;4(3):462-471 [PMID: 27352117]
  46. J Affect Disord. 2018 Jan 15;226:28-35 [PMID: 28942203]
  47. J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):170-5 [PMID: 16510861]
  48. Ethn Dis. 2009 Autumn;19(4):396-400 [PMID: 20073139]
  49. J Clin Hypertens (Greenwich). 2015 Aug;17(8):614-21 [PMID: 25923581]
  50. Can J Aging. 2017 Mar;36(1):97-107 [PMID: 28091333]
  51. J Gerontol A Biol Sci Med Sci. 2015 Aug;70(8):989-95 [PMID: 25733718]
  52. BMJ. 2003 Sep 27;327(7417):712-7 [PMID: 14512478]
  53. Br J Clin Pharmacol. 2004 Dec;58(6):648-64 [PMID: 15563363]
  54. Med Care Res Rev. 2007 Oct;64(5 Suppl):101S-56S [PMID: 17881626]
  55. J Am Geriatr Soc. 2003 Jun;51(6):841-6 [PMID: 12757573]
  56. Am Heart J. 2013 May;165(5):665-78, 678.e1 [PMID: 23622903]
  57. Hypertension. 2013 May;61(5):964-71 [PMID: 23478096]
  58. MMWR Morb Mortal Wkly Rep. 2016 Sep 23;65(37):993-998 [PMID: 27656914]
  59. J Pain. 2007 Jan;8(1):75-84 [PMID: 16949874]
  60. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8 [PMID: 24310148]
  61. BMC Geriatr. 2017 Jul 25;17(1):163 [PMID: 28743244]
  62. Age Ageing. 2008 Jan;37(1):96-101 [PMID: 17933759]

Grants

  1. R25 MD007610/NIMHD NIH HHS
  2. U54 MD007598/NIMHD NIH HHS
  3. U54MD007598/NIMHD NIH HHS

MeSH Term

Black or African American
Aged
Aged, 80 and over
Antihypertensive Agents
Chronic Disease
Comorbidity
Cross-Sectional Studies
Drug Interactions
Female
Humans
Hypertension
Inappropriate Prescribing
Male
Polypharmacy
Potentially Inappropriate Medication List
Prevalence

Chemicals

Antihypertensive Agents

Word Cloud

Created with Highcharts 10.0.0useadultsPIMchronicPIMsolderconditionsamongparticipantsmedicationsPotentiallystudyhypertensiveAfrican-AmericannumberinappropriatemedicationdrugsinteractionspatientfunctionalprioritiesInappropriatemajorAGSunderservednon-institutionalizedpotentialAlmostonedrug-drugNearlyhigherreportedmaygoalsimpactcanBACKGROUND:particularlyminorityco-morbidityremainspublichealthconcernAmericanGeriatricsSocietyreportsMedicationcontinuesprescribeddespiteevidencepooroutcomesmainobjectiveexamineprevalenceFurthermoreexaminescorrelationstypeMETHODS:cross-sectionalcomprisedconveniencesample193aged65 yearsrecruitedseveralseniorhousingunitslocatedareasSouthLosAngelesupdated2015BeersCriteriausedidentifyusingRESULTS:twoaveragetaken087rangeseven23%duecommonprotonpumpinhibitorsPPICentralNervousSystemCNSactiveagents56%potentiallyincreasedriskfallsfall-associatedbonefracturessignificantly70%sufferingpainCONCLUSIONS:reasonhighlevelspolypharmacydrugpatientssuffermultiplepossiblenecessarytreatThereforecareexplicitlyreviewedorderdeterminemanygreatestlifeand/orlimitedpatient'scauseharmfulreducedeliminatedremainingfocusimportantFallsMinorityOlderPain

Similar Articles

Cited By